Early Beleodaq win for Spectrum bodes well for Onxeo

The FDA on 3 July surprised Spectrum Pharmaceuticals and its partner Topotarget – which is finalizing a merger with BioAlliance to form Onxeo – by granting approval of Beleodaq (belinostat) more than a month ahead of schedule as a treatment for patients with peripheral T-cell lymphoma (PTCL), a diverse group of rare and aggressive diseases, which account for up to 15% of all non-Hodgkin lymphomas.

Shares of Henderson, Nevada-based Spectrum jumped 6.3%, or 55 cents, in morning trading on 3 July.